Literature DB >> 12087419

CTLA-4: new insights into its biological function and use in tumor immunotherapy.

Jackson G Egen1, Michael S Kuhns, James P Allison.   

Abstract

The discovery of multiple costimulatory cell surface molecules that influence the course of T cell activation has increased our appreciation of the complexity of the T cell response. It remains clear, however, that CD28 and cytotoxic T lymphocyte antigen 4 (CTLA-4) are the critical costimulatory receptors that determine the early outcome of stimulation through the T cell antigen receptor (TCR). Details of how the T cell integrates TCR stimulation with the costimulatory signals of CD28 and the inhibitory signals of CTLA-4 remain to be established, but unique features of the cell biology of CTLA-4 provide important insights into its function. We summarize here recent findings that suggest a previously unrecognized role for CTLA-4 in the regulation of T cell responses. We also describe preclinical and clinical results that indicate manipulation of CTLA-4 has considerable promise as a strategy for the immunotherapy of cancer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12087419     DOI: 10.1038/ni0702-611

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  257 in total

Review 1.  Universes collide: combining immunotherapy with targeted therapy for cancer.

Authors:  Jennifer A Wargo; Zachary A Cooper; Keith T Flaherty
Journal:  Cancer Discov       Date:  2014-11-13       Impact factor: 39.397

Review 2.  Blockade of cytotoxic T-lymphocyte antigen-4 as a new therapeutic approach for advanced melanoma.

Authors:  Xiang-Yang Wang; Daming Zuo; Devanand Sarkar; Paul B Fisher
Journal:  Expert Opin Pharmacother       Date:  2011-12       Impact factor: 3.889

Review 3.  Genetic variants associated with breast-cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence.

Authors:  Ben Zhang; Alicia Beeghly-Fadiel; Jirong Long; Wei Zheng
Journal:  Lancet Oncol       Date:  2011-04-20       Impact factor: 41.316

4.  Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.

Authors:  Bishnu P Nayak; Gangadhara Sailaja; Abdul M Jabbar
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

5.  B7x: a widely expressed B7 family member that inhibits T cell activation.

Authors:  Xingxing Zang; P'ng Loke; Jayon Kim; Kenneth Murphy; Rebecca Waitz; James P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-14       Impact factor: 11.205

Review 6.  Progress on new vaccine strategies for the immunotherapy and prevention of cancer.

Authors:  Jay A Berzofsky; Masaki Terabe; SangKon Oh; Igor M Belyakov; Jeffrey D Ahlers; John E Janik; John C Morris
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

7.  Visualization of Cell-Cell Interaction Contacts: Synapses and Kinapses.

Authors:  Michael L Dustin
Journal:  Self Nonself       Date:  2011-04-01

8.  CTLA-4 on alloreactive CD4 T cells interacts with recipient CD80/86 to promote tolerance.

Authors:  Josef Kurtz; Forum Raval; Casey Vallot; Jayden Der; Megan Sykes
Journal:  Blood       Date:  2009-01-29       Impact factor: 22.113

9.  Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.

Authors:  William L Redmond; Stefanie N Linch; Melissa J Kasiewicz
Journal:  Cancer Immunol Res       Date:  2013-11-11       Impact factor: 11.151

Review 10.  Enhancing efficacy of therapeutic vaccinations by combination with other modalities.

Authors:  James L Gulley; Ravi A Madan; Philip M Arlen
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.